Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. insiders are currently net sellers of CRNX stock, showing neutral sentiment over the past 90 days. Total sales of $82.1M outpace purchases of $76.2M, creating a net outflow of $5.9M. However, 58% of these sales are pre-scheduled 10b5-1 plan transactions.

Crinetics Pharmaceuticals, Inc. has 28 active insiders who have filed SEC Form 4 transactions in the past 90 days. Life Sciences Master Fund Ltd Perceptive (Executive) leads with 5 transactions totaling $30.3M. Richard Scott Struthers (Executive) follows with 51 transactions worth $25.8M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Crinetics Pharmaceuticals, Inc.'s current score of 48/100 indicates neutral insider sentiment. Scores between 40-60 represent neutral or mixed activity. With $76.2M in purchases and $82.1M in sales, no strong directional conviction is evident.

The most recent insider transaction occurred on Mar 3, 2026, when Schilke Tobin (Chief Financial Officer) disposed of 6,713 shares at $39.67 per share for $266.3K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, CRNX insider trading sentiment is currently neutral with an Alignment Score of 48/100. The balanced activity—$76.2M bought vs $82.1M sold—suggests no strong consensus among insiders.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Crinetics Pharmaceuticals, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At CRNX, we track all Form 4 filings—currently showing 381 transactions from 28 insiders over 90 days.

A 10b5-1 plan allows Crinetics Pharmaceuticals, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At CRNX, approximately 58% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 28 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Crinetics Pharmaceuticals, Inc.'s current score of 48/100 indicates neutral sentiment with balanced buying and selling activity. This is calculated from $76.2M in purchases versus $82.1M in sales over 90 days, resulting in a net flow of -$5.9M.

SEC Form 4 filings are mandatory reports that Crinetics Pharmaceuticals, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At CRNX, the most common type is "M" with 28 occurrences. The most recent Form 4 was filed on Mar 3, 2026 by Schilke Tobin.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Crinetics Pharmaceuticals, Inc., approximately 58% of recent transactions are executed under 10b5-1 plans, while 42% appear to be discretionary trades. This high percentage suggests selling activity may be routine diversification.